November 5, 2020
In oncology, many manufacturers go into niche indications, where there are very specific tumors, and then they opt for..
October 22, 2020
In this two-part blog series, we interview Bart Heeg, Vice President HEOR and Founder at Ingress Health (A Cytel..
October 20, 2020
In this interview with Thomas Wilke, Principal Scientist at Ingress-Health (a Cytel company), we talk to him about his..
October 19, 2020
COVID-19 has created extreme uncertainties -- a dearth of historical information combined with the need for safety,..
October 14, 2020
A credible evidence base is needed to support and document the economic value of new technologies and therapeutic..
September 10, 2020
Single arm trials are emerging as an accepted way of assessing a new treatment intervention. They establish clinical..
August 7, 2020
Recently a biotech approached Cytel for support with a Phase 2 Study in oncology. Regulators had requested a natural..
August 5, 2020
Cytel is conducting two pilot projects on head-to-head comparisons using real world data. These projects in oncology..
July 30, 2020
A new peer-reviewed article co-authored by several Cytel scientists re-examines the way in which adaptive trials are..